S

Soumyakiran

Active Director Director DIN 07688412
DIN 07688412 First appointment Jan 2017 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2017
Shareholding value •••• Premium profile

About Soumyakiran

Data last updated:

Soumyakiran is a Director at Novell Biolabs Private Limited (since 2017). The company operates in Pharma. Novell Biolabs Private Limited reported revenue of ₹1.09 Cr (FY 2024).

DIN 07688412
Primary Designation Director
Industry Pharma
First Appointment 05 Jan 2017
Oldest Company Age 17 yrs
Largest company Novell Biolabs Private Limited · ₹1.09 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Novell Biolabs Private Limited U51397KA2009PTC049944
Director05 Jan 20172009₹1.09 Cr (FY 2024)Active

Board colleagues of Soumyakiran

NameDINCompanyDesignation
Mandadhi Kiran Kumar02629497Novell Biolabs Private LimitedManaging Director

Directorship timeline

Open interactive timeline →
Novell Biolabs Private Limited
Premium access

Shareholding and investment profile for Soumyakiran

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Soumyakiran

Soumyakiran currently holds 1 directorship: Novell Biolabs Private Limited (Director, since 05 Jan 2017, revenue ₹1.09 Cr (FY 2024)).

Soumyakiran was first appointed on 05 Jan 2017 as Director at Novell Biolabs Private Limited.

The current boards of Soumyakiran's companies include Mandadhi Kiran Kumar (Novell Biolabs Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available